Results 61 to 70 of about 18,364 (184)
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Naltrexone extended-release injection: an option for the management of opioid abuse
Substance Abuse and Rehabilitation, 2011 Robert Taylor Jr1, Robert B Raffa2, Joseph V Pergolizzi Jr3,41NEMA Research Inc, Naples, FL, 2Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA, 3Department of Medicine, Johns Hopkins University School of ...
Taylor Jr R, Raffa RB, Pergolizzi Jr JV
doaj
Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders
British Journal of Pharmacology, EarlyView.Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman +3 more
wiley +1 more source
McGill Journal of MedicineIntroduction: Naltrexone is an opioid receptor antagonist prescribed for alcohol use disorder and opioid use disorder. Naltrexone has a high affinity for the mu-opioid receptors, which are the primary binding site of beta-endorphin.
Caitlin Collier, Thomas Hilton
doaj +1 more source
Neurobiology of Disease, 2005 Storage of motor memory involves the basal ganglia and more precisely the striatum, which receives afferents from all regions of the cerebral cortex.
Pershia Samadi +3 more
doaj +1 more source
Clinical Obesity, Volume 15, Issue 2, April 2025.Summary This study examined the change in weight at 6 months of naltrexone/bupropion (NB), a combination pharmacological therapy for weight management, in real‐world practice in Canada. The study was conducted through an observational, retrospective, single‐arm chart review of adult patients who attended the Wharton Medical Clinic in Ontario, Canada ...
Sean Wharton +4 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To describe obesity treatments in real‐world settings after discontinuation of semaglutide or tirzepatide and variability in weight change post‐discontinuation. Materials and Methods This retrospective cohort study used electronic health records from 1 January 2021, to 30 June 2025, in a large health system in Ohio and Florida.
Hamlet Gasoyan +9 more
wiley +1 more source
Translational PsychiatryThe development of medications for alcohol use disorders (AUD) faces stagnation, as promising drugs failed to translate in clinic. Screening on homogeneous groups of animals drugs later tested on heterogeneous clinical cohorts may contribute to the ...
Sara De Carlo +15 more
doaj +1 more source
Acta Cirúrgica Brasileira, 2012 PURPOSE: To investigate the effect of the opioid blocker naltrexone in the inflammatory response in acute pancreatitis (AP). METHODS: Acute pancreatitis was induced in anesthetized male Wistar rats by retrograde injection of 2.5% sodium taurocholate ...
Artur Penido +5 more
doaj +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To evaluate the association between semaglutide 2.4 mg and major adverse cardiovascular events (MACE) among adults with clinical atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity without diabetes in real‐world clinical practice.
Michael G. Nanna +10 more
wiley +1 more source